Skip to content

Nordic Nanovector Capital Markets Day 2017

22.11.2017 07:24

Nordic Nanovector ASA (OSE: NANO) hosts its Capital Markets Day (CMD) today in Oslo.

Oslo, Norway, 22 November 2017

The presentations will be held by members of the executive management team as well as selected external expert speakers, including Prof. Pier Luigi Zinzani, Associate Professor of Haematology, Institute of Haematology, University of Bologna; and Dr. Arne Kolstad, Senior consultant in Medical Oncology and Radiotherapy, Oslo University Hospital Radiumhospitalet and leading investigator of the LYMRIT 37-01 Phase 1/2 study. Highlights of the third quarter 2017 report will be presented towards the end of the programme.

Highlights of the CMD:

• Evolving treatment landscape and attractive opportunities for Betalutin® in NHL, where there is a significant unmet medical need;

• Strong preliminary results from the Phase 1/2 LYMRIT 37-01 clinical study in 3rd line relapsed/refractory follicular lymphoma (3L R/R FL), which provide a promising outlook for Betalutin® as a differentiated, competitive product;

• Rationale for and design of the pivotal Phase 2b PARADIGME trial with Betalutin®, which is intended to provide a robust means to identify the best dosing regimen and to provide the best clinical data to support filing for approval, and which the company is close to initiating;

• Key learnings from an extensive market research programme that have equipped the company with valuable knowledge about the US healthcare environment, the NHL market and target customers. These insights will guide the company’s future strategy with Betalutin® to support its successful commercialisation.

• Outline of the company’s strategy to maximize the value of Betalutin® in NHL.

The event will start at 10:00 CET at Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo. A link to the live webcast and subsequent recording will be available at in the Investor and Media section. All presentations will be available at www.nordicnanovector.comin the section: investors-and-media/reports-and-presentations/presentations/2017.

For further information, please contact:

IR enquiries

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76


Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.

Further information about the Company can be found at

Forward-looking statements

This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Source: Nordic Nanovector